[go: up one dir, main page]

EP1842068A1 - Utilisation de cytometrie de flux multiparametrique pour diagnostic, pronostique et validation d'immunotherapies pour malades autoimmunes, hematologiques et lymphoproliferatives - Google Patents

Utilisation de cytometrie de flux multiparametrique pour diagnostic, pronostique et validation d'immunotherapies pour malades autoimmunes, hematologiques et lymphoproliferatives

Info

Publication number
EP1842068A1
EP1842068A1 EP04745177A EP04745177A EP1842068A1 EP 1842068 A1 EP1842068 A1 EP 1842068A1 EP 04745177 A EP04745177 A EP 04745177A EP 04745177 A EP04745177 A EP 04745177A EP 1842068 A1 EP1842068 A1 EP 1842068A1
Authority
EP
European Patent Office
Prior art keywords
cells
apc
fitc
autoimmune
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04745177A
Other languages
German (de)
English (en)
Inventor
Gionvanna Borsellino
Adamo Diamantini
Luca Battistini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Santa Lucia Irccs
Original Assignee
Fondazione Santa Lucia Irccs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Santa Lucia Irccs filed Critical Fondazione Santa Lucia Irccs
Publication of EP1842068A1 publication Critical patent/EP1842068A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/42—Low-temperature sample treatment, e.g. cryofixation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1477—Multiparameters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Definitions

  • This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations; these antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed study of neoplastic cell populations (when screening for haematological diseases).
  • the increased knowledge on how the immune system works has brought, in recent years, to a better understanding of the pathogenesis of many diseases, and, consequently, to new therapeutic approaches.
  • the interactions between the different components of the immune system are indeed very complex, and new technologies have revealed that cellular populations Which apparently seem homogeneous are in fact composed of several subpopulations with different phenotypes and functions.
  • the cells of the immune system circulate in the blood and the lymph which can also migrate to tissue to protect the organism efficiently. Lymphocytes specifically recognise and respond to foreign antigens, while phagocytes and granulocytes are classified as "inflammatory" cells, and they play a major role in the innate immune response.
  • lymphocytes appear to be macroscopically homogeneous, they can actually be divided in distinct subpopulations: in the first place one must distinguish between B-lymphocytes, which produce antibodies, and T lymphocytes. Based on expression of surface molecules, the latter can be further divided in CD4+ "helper” cells and CD8+ cytotoxic cells. Both CD4+ and CD8+ cells comprise subsets, which have not yet encountered a foreign antigen, so called “na ⁇ ve" cells, and memory cells, which represent the expanded pool of antigen experienced cells. But these subsets are still heterogeneous: indeed some memory cells produce proinflammatory proteins, while other tend to regulate and to switch off the immune response.
  • the complexity of the immune system is such that the identification of cellular subsets with unique functional characteristics requires the simultaneous measurement of multiple parameters on each single cell.
  • multiparametric flow cytometry it is possible to measure the presence of surface markers, which permit the identification of distinct cellular subsets: for instance, during a viral infection, it is possible to identify virus-specific cells activated by the infection and to follow them during the anti-viral response.
  • virus-specific cells activated by the infection and to follow them during the anti-viral response.
  • the cells of the immune system become activated and acquire the functions which permit the elimination of the offending agent.
  • adhesion molecules which enable the cells of the immune system to interact with the endothelial cells lining the capillaries: this interaction represents the initial step of the migration process by which the cells of the immune system gain access to inflamed tissues.
  • the study of the membrane receptors expressed by the different subsets of lymphocytes represents a powerful tool for the evaluation of the "immunological status" of an individual.
  • autoimmune diseases are the results of the dysregulation of the complex interactions between cells of the immune system, so these pathologies represent a good target for studies involving the definition of fine cellular subsets.
  • Flow cytometry represents the ideal tool for the study of non adherent cells (in suspension), and can be used also for the study of lymphoid tissues, from which single cell suspensions can be easily obtained. Data obtained with flow cytometry - both concerning the distribution of the different cellular subsets and the expression of multiple cellular markers are then evaluated with powerful software.
  • Fig. 1 show the multiparametric analysis of CD3+CD8+ lymphocytes obtained from the peripheral blood of a healthy subject.
  • Fig.2. show the multiparametric analysis of CD3+CD8+ lymphocytes in an MS patient
  • Fig.3. show the analysis of the ability of CD3+CD8+ lymphocytes to produce the inflammatory cytokine interferon gamma (IFN ⁇ ).
  • This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations.
  • These antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed study of neoplastic cell populations (when screening for haematological diseases).
  • Antibodies are aliquoted in small tubes at predetermined concentrations, and then lyophilised.
  • Antibodies which we have tested are: CD3 PE-Cy7, CD8 PE-Cy7, CD8 PE-TxRed, CD45RA PE-TxRed, CD62L PE-TxRed, CD45RO PE-TxRed, CD8 beta PE, CD49dFlTC, NKRP1A PE, CD3 FITC, CD3 PE, CD8 FITC, CD8 PE, CD8 CyChrome, CD8 APC, CD4 FITC, CD4 APC, CD62L PE-Cy5, CD62L APC, CD162 PE, CCR7 PE, CD45RO FITC, CD11a PE, CD11a APC, CD49d PE, CD8 APC-Cy7, CDHa ' FITC, CD45RA PE-Cy5, CD5 PE-Cy5, CD23 PE-TxRed, CD19 PE-Cy7, CD19 APC- Cy7, CD79b APC, CD38 PE, kappa FITC, lambda PE, F
  • Antibodies are used are optimal predetermined concentrations, (usually 0,25 ⁇ g/ml). Each new antibody lot is accurately tested in serial dilutions, and antibodies are aliquoted in 1 ,5 ml tubes in different combinations. Tubes are then put in the speedvac, until completely lyophilised (20 minutes). Before use each antibody combinations is reconstituted with saline solution, and added to the tube containing cells to be analyzed. For each antibody combination, 2x10 6 cells are stained. This method can be used for staining of whole blood or of peripheral blood lymphocytes (PBLs) obtained from centrifugation on a density gradient.
  • PBLs peripheral blood lymphocytes
  • heparinized blood will be diluted with 1 volume of RPMI media and gently layered over the Fycoll-Hypaque (Pharmacia). Following centrifugation at 660g for 30 minutes, cells at the interface of the gradient will be collected and washed three times in medium. After the final wash cells will be resuspended in PBS with 1% human serum. For each labelling cells will be resuspended in a volume of 100 ⁇ l. All antibodies will have been tested at saturating conditions, to exclude differences in staining.
  • Samples will then be acquired at the flow cytometer using constant instrument settings, obtained by a careful daily calibration of the instruments with beads and by the use of appropriate compensation controls (beads coated with the antibodies used in the stainings). For each sample 1x106 events will be acquired, in order to guarantee an appropriate representation of all cellular subsets, and allowing significant statistical analysis.
  • To study cytokine production we will follow the procedure of intracellular staining, as established in our laboratory. Briefly, cells are plated at a density of 2x10 6 /ml in 96 well plates and triggered with either mitogens (PHA, PMA+ionomycin) or antibodies directed against cell surface molecules (such as CD3), for 6 hours at 37°C, in the presence of monensin (10 mM).
  • Flow cytometric analysis permits not only the phenotypic analysis of cellular subpopulations r but also the ability of each subpopulation to produce soluble factors which modulate the immune response (Fig. 3).
  • the panel of cytokine produced by each cell type provides important information on the immunological status of the patient, and can be used as a "marker" of the efficacy of immunomodulatory treatments.
  • this invention may be used for the diagnosis of hematologic and lymphoproliferative disorders.
  • flow cytometry is a powerful tool used for the characterization of neoplastic cells present in these diseases.
  • the ability to simultaneously measure multiple markers on each ' single cell enables to carry out a detailed analysis of tumoral cells, and to perform an accurate diagnosis.
  • the diagnosis of hematologic tumours requires an accurate characterization of the neoplastic clone, since treatment and prognosis depend closely on the diagnosis.
  • a standard panel of antibodies specific for membrane or cytoplasmic markers is used in order to define the lineage and differentiation stage of the neoplastic clone (Tab.1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne un procédé permettant d'effectuer une analyse cytométrique de flux à l'aide de combinaisons d'anticorps déterminées. Ces anticorps sont conjugués à différents fluorochromes, et les combinaisons d'anticorps comprennent plusieurs panels qui permettent effectuer une analyse du statut immunologique de l'individu (en cas de dépistage de troubles autoimmuns ou d'infections chroniques) ou une étude détaillée de populations de cellules néoplasiques (lors du dépistage de maladies hématologiques). Les anticorps sont répartis dans de petits tubes selon des concentrations prédéterminées, puis lyophilisés.
EP04745177A 2004-06-21 2004-06-21 Utilisation de cytometrie de flux multiparametrique pour diagnostic, pronostique et validation d'immunotherapies pour malades autoimmunes, hematologiques et lymphoproliferatives Withdrawn EP1842068A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2004/000352 WO2005124350A1 (fr) 2004-06-21 2004-06-21 Utilisation de cytometrie de flux multiparametrique pour diagnostic, pronostique et validation d'immunotherapies pour malades autoimmunes, hematologiques et lymphoproliferatives

Publications (1)

Publication Number Publication Date
EP1842068A1 true EP1842068A1 (fr) 2007-10-10

Family

ID=34957987

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04745177A Withdrawn EP1842068A1 (fr) 2004-06-21 2004-06-21 Utilisation de cytometrie de flux multiparametrique pour diagnostic, pronostique et validation d'immunotherapies pour malades autoimmunes, hematologiques et lymphoproliferatives

Country Status (2)

Country Link
EP (1) EP1842068A1 (fr)
WO (1) WO2005124350A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148101B2 (en) 2008-07-22 2012-04-03 Abbott Laboratories Method for classifying and counting bacteria in body fluids
CN102062774B (zh) * 2009-11-13 2013-08-21 程小星 检测结核病治疗效果的试剂盒
US20160024473A1 (en) * 2013-03-08 2016-01-28 Cells For Cells Menstrual stems cells for the efficient support and expansion of cd34+ cd133+ hematopoietic stem cells in vitro
US11698367B2 (en) * 2017-09-15 2023-07-11 Beckman Coulter, Inc. Flow based assays for therapeutics
CN109030322A (zh) * 2018-08-17 2018-12-18 成都赋智健康科技有限公司 一种节约成本的流式细胞术检测方法
US20210389225A1 (en) * 2018-12-01 2021-12-16 Mingdao Innovation (Beijing) Medical-Tech Co., Ltd. A flow cytometric detection method for lymphocyte in immune cells
CN110488009B (zh) * 2019-04-12 2023-09-05 北京市理化分析测试中心 一种非疾病诊断目的的人体免疫功能的检测方法及应用
CN110412286A (zh) * 2019-07-11 2019-11-05 上海宸安生物科技有限公司 一种利用质谱流式系统对肿瘤样本进行单细胞检测的方法
CN114112868B (zh) * 2020-08-26 2024-12-13 上海睿昂基因科技股份有限公司 一种用于监测肿瘤相关免疫微环境的流式细胞术试剂盒及监测方法
CN114578048B (zh) * 2021-12-22 2023-08-08 重庆医科大学附属儿童医院 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒
CN119178711B (zh) * 2024-11-25 2025-02-25 国家卫生健康委科学技术研究所 在流式细胞仪上检测自然杀伤细胞的方法及其试剂盒
CN119530150A (zh) * 2024-11-29 2025-02-28 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤反应性非耗竭t细胞亚型及其分离、鉴定方法
CN119290541B (zh) * 2024-12-13 2025-04-04 天津医科大学总医院空港医院 一种淋巴组织中b细胞亚群的检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1603395A (en) * 1994-01-21 1995-08-08 Coulter Corporation Solid tumor analysis by multiparametric flow cytometry
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005124350A1 *

Also Published As

Publication number Publication date
WO2005124350A1 (fr) 2005-12-29

Similar Documents

Publication Publication Date Title
EP0559738B1 (fr) Procedes servant a detecter et a quantifier la presence de sous-ensembles cellulaires dans des sous-populations d'une population de cellules melangees
Esparza et al. Neutrophil function in elderly persons assessed by flow cytometry
WO1988008538A1 (fr) Test et dispositif de determination du profil immunologique
WO2005124350A1 (fr) Utilisation de cytometrie de flux multiparametrique pour diagnostic, pronostique et validation d'immunotherapies pour malades autoimmunes, hematologiques et lymphoproliferatives
JP2004533855A (ja) 細胞計数
JP2001091513A (ja) 白血球の分類計数方法
US6630316B1 (en) Method for measurement of lymphocyte function
US5108904A (en) CD44 as a marker for HIV infection
Terstappen et al. Physical discrimination between human T‐lymphocyte subpopulations by means of light scattering, revealing two populations of T8‐positive cells
WO2012062831A1 (fr) Procédé de diagnostic et / ou de suivi de l'évolution d'une tumeur
CN111537735A (zh) 抗体检测试剂盒以及在免疫分析方面的应用
Prince et al. CD69 expression reliably predicts the anti-CD3-induced proliferative response of lymphocytes from human immunodeficiency virus type 1-infected patients
CN111504886B (zh) 一组分子在制备新冠肺炎辅助诊断试剂或试剂盒中的应用
CN105547971B (zh) 细胞毒性t细胞脱颗粒的流式细胞术检测方法
WO1997012244A1 (fr) Methode de determination des caracteristiques de repartition de lymphocytes t chez des sujets immunodeprimes
US7169571B2 (en) Methods for measurement of lymphocyte function
CN117384289A (zh) 检测t细胞大颗粒淋巴细胞的抗体组合、试剂盒及其应用
Lavigne et al. Identification and analysis of eosinophils by flow cytometry using the depolarized side scatter‐saponin method
Thornthwaite et al. Dual immunofluorescent analysis of human peripheral blood lymphocytes
CN115327135A (zh) 中性粒细胞cd64感染指数的测定试剂及其测定方法
US20020160429A1 (en) Method for binding basophils and mast cells
CN115004032A (zh) 一种用于检测cd141+树突状细胞亚群表型和功能的方法及其应用试剂盒
US20040110122A1 (en) Three-color reagent for measurement of CD4 positive lymphocytes by flow cytometry
El‐Awar et al. Discrimination of T, B, and Null Lymphocytes by Electronic Sizing1
US20070243576A1 (en) Method to confirm immunosuppression in human patients by measuring lymphocyte activation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BATTISTINI, LUCA

Inventor name: DIAMANTINI, ADAMO

Inventor name: BORSELLINO, GIONVANNA

17Q First examination report despatched

Effective date: 20081020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101103